Show simple item record

Files in this item

Item metadata

dc.contributor.advisorWhite, Malcolm F.
dc.contributor.authorZhu, Wenlong
dc.coverage.spatialxiii, 201 p.en_US
dc.date.accessioned2022-05-12T10:54:43Z
dc.date.available2022-05-12T10:54:43Z
dc.date.issued2022-06-15
dc.identifier.urihttps://hdl.handle.net/10023/25349
dc.description.abstractProkaryotes have a wide range of antiviral strategies to defend against invading mobile genetic elements (MGEs). Type III CRISPR-Cas systems typically synthesise cyclic oligoadenylate (cOA) second messengers upon binding to cognate foreign RNA. These second messengers allosterically activate type III CRISPR ancillary proteins, potentiating a powerful immune response. Following the discovery of cOA signalling pathway, several ancillary proteins from Csx1/Csm6 family had been described. They sense cOA molecules with their CARF (CRISPR associated Rossman fold) domains and non-specifically cleave RNA with their effector domains. Here, we describe the structure and mechanism of two novel ancillary proteins Can1 and Can2. Can1 has a unique monomeric architecture that contains two CARF domains, a PD-(D/E)XK nuclease domain and a nuclease-like domain. It favours nicking scDNA in the presence of cyclic tetra-adenylate (cA₄) and metal ions. Can2 forms a canonical homodimer and each monomer contains a CARF domain and a PD-(D/E)XK nuclease domain. It exhibits both DNase and RNase activity in the presence of cA₄ and metal ions. It also provides effective immunity against plasmid and bacteriophage infection in a recombinant type III CRISPR-Cas system.en_US
dc.description.sponsorship"This work was supported by grants from the Biotechnology and Biological Sciences Research Council (BB/S000313/1 to M.F.W., BB/R008035/1 to T.M.G. and BB/T004789/1 to M.F.W. and T.M.G.); grants from Wellcome Trust Institutional Strategic Support Funding (204821/Z/16/Z to M.F.W. and T.M.G.); grants from China Scholarship Council (201703780015 to W.Z.). Funding for open access charge: RCUK block grant." -- Fundingen
dc.language.isoenen_US
dc.rightsCreative Commons Attribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCRISPRen_US
dc.subjectCyclic oligoadenylateen_US
dc.subjectCARFen_US
dc.subjectNucleaseen_US
dc.subjectAntiviral strategyen_US
dc.titleStructure and mechanism of two type III CRISPR defence nucleases activated by cyclic oligoadenylateen_US
dc.typeThesisen_US
dc.contributor.sponsorChina Scholarship Council (CSC)en_US
dc.contributor.sponsorBiotechnology and Biological Sciences Research Council (BBSRC)en_US
dc.contributor.sponsorWellcome Trust. Institutional Strategic Support Fund (ISSF)en_US
dc.contributor.sponsorResearch Councils UK (RCUK)en_US
dc.type.qualificationlevelDoctoralen_US
dc.type.qualificationnamePhD Doctor of Philosophyen_US
dc.publisher.institutionThe University of St Andrewsen_US
dc.identifier.doihttps://doi.org/10.17630/sta/167
dc.identifier.grantnumber201703780015en_US
dc.identifier.grantnumberBB/S000313/1en_US
dc.identifier.grantnumberBB/R008035/1en_US
dc.identifier.grantnumberBB/T004789/1en_US
dc.identifier.grantnumber204821/Z/16/Zen_US


The following licence files are associated with this item:

    This item appears in the following Collection(s)

    Show simple item record

    Creative Commons Attribution 4.0 International
    Except where otherwise noted within the work, this item's licence for re-use is described as Creative Commons Attribution 4.0 International